{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:39:25Z","timestamp":1781332765530,"version":"3.54.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1191221"],"award-info":[{"award-number":["OPP1191221"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Therapeutic drug monitoring (TDM) for personalized dosing of fluoroquinolones has been recommended to optimize efficacy and reduce acquired drug resistance in the treatment of MDR TB. Therefore, the aim of this study was to develop a simple, low-cost, robust assay for TDM using mobile UV\/visible light (UV\/VIS) spectrophotometry to quantify levofloxacin in human saliva at the point of care for TB endemic settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All experiments were performed on a mobile UV\/VIS spectrophotometer. The levofloxacin concentration was quantified by using the amplitude of the second-order spectrum between 300 and 400\u2009nm of seven calibrators. The concentration of spiked samples was calculated from the spectrum amplitude using linear regression. The method was validated for selectivity, specificity, linearity, accuracy and precision. Drugs frequently co-administered were tested for interference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The calibration curve was linear over a range of 2.5\u201350.0\u2009mg\/L for levofloxacin, with a correlation coefficient of 0.997. Calculated accuracy ranged from \u20135.2% to 2.4%. Overall precision ranged from 2.1% to 16.1%. Application of the Savitsky\u2013Golay method reduced the effect of interferents on the quantitation of levofloxacin. Although rifampicin and pyrazinamide showed analytical interference at the lower limit of quantitation of levofloxacin concentrations, this interference had no implication on decisions regarding the levofloxacin dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A simple UV\/VIS spectrophotometric method to quantify levofloxacin in saliva using a mobile nanophotometer has been validated. This method can be evaluated in programmatic settings to identify patients with low levofloxacin drug exposure to trigger personalized dose adjustment.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa420","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T12:25:38Z","timestamp":1600345538000},"page":"423-429","source":"Crossref","is-referenced-by-count":33,"title":["A mobile microvolume UV\/visible light spectrophotometer for the measurement of levofloxacin in saliva"],"prefix":"10.1093","volume":"76","author":[{"given":"Jan-Willem C","family":"Alffenaar","sequence":"first","affiliation":[{"name":"University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia"},{"name":"Westmead Hospital, Sydney, Australia"},{"name":"Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia"},{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin M","family":"Jongedijk","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A J","family":"van Winkel","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha","family":"Sariko","sequence":"additional","affiliation":[{"name":"Kibong\u2019oto Infectious Diseases Hospital, Kilimanjaro, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K","family":"Heysell","sequence":"additional","affiliation":[{"name":"University of Virginia, Division of Infectious Diseases and International Health, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stellah","family":"Mpagama","sequence":"additional","affiliation":[{"name":"Kibong\u2019oto Infectious Diseases Hospital, Kilimanjaro, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J","family":"Touw","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"2021012006025969300_dkaa420-B1","year":"2019"},{"key":"2021012006025969300_dkaa420-B2","year":"2019"},{"key":"2021012006025969300_dkaa420-B3","year":"2019"},{"key":"2021012006025969300_dkaa420-B4","doi-asserted-by":"crossref","first-page":"1700173","DOI":"10.1183\/13993003.00173-2017","article-title":"Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis","volume":"49","author":"Davies Forsman","year":"2017","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021012006025969300_dkaa420-B6","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"2021012006025969300_dkaa420-B7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00176610","article-title":"Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience","volume":"38","author":"Pranger","year":"2011","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B8","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021012006025969300_dkaa420-B9","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021012006025969300_dkaa420-B10","first-page":"e00343","article-title":"Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients","volume":"61","author":"Van\u2019t Boveneind-Vrubleuskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012006025969300_dkaa420-B11","doi-asserted-by":"crossref","first-page":"1802107","DOI":"10.1183\/13993003.02107-2018","article-title":"Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients","volume":"53","author":"Ghimire","year":"2019","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B12","doi-asserted-by":"crossref","first-page":"e00770","DOI":"10.1128\/AAC.00770-18","article-title":"Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012006025969300_dkaa420-B13","doi-asserted-by":"crossref","first-page":"e00279","DOI":"10.1128\/AAC.00279-19","article-title":"Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic\/pharmacodynamic target attainment to guide dose selection","volume":"63","author":"Al-Shaer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012006025969300_dkaa420-B14","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021012006025969300_dkaa420-B15","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2021012006025969300_dkaa420-B16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trac.2015.11.026","article-title":"LC-MS\/MS for therapeutic drug monitoring of anti-infective drugs","volume":"84","author":"Veringa","year":"2016","journal-title":"Trends Anal Chem"},{"key":"2021012006025969300_dkaa420-B17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1183\/13993003.01285-2015","article-title":"End TB with precision treatment!","volume":"47","author":"van der Burgt","year":"2016","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B18","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1183\/13993003.00040-2016","article-title":"Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics","volume":"47","author":"Ghimire","year":"2016","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B19","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"2021012006025969300_dkaa420-B20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(20)30049-0","article-title":"Challenging the management of drug-resistant tuberculosis","volume":"395","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"2021012006025969300_dkaa420-B21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/cid\/ciw677","article-title":"Therapeutic drug monitoring in tuberculosis: practical application for physicians","volume":"64","author":"Alffenaar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021012006025969300_dkaa420-B22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/cid\/ciy787","article-title":"Therapeutic drug monitoring: the need for practical guidance","volume":"68","author":"Alffenaar","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021012006025969300_dkaa420-B23","doi-asserted-by":"crossref","first-page":"e02379","DOI":"10.1128\/AAC.02379-18","article-title":"Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in patients with multidrug-resistant tuberculosis","volume":"63","author":"Ghimire","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012006025969300_dkaa420-B24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FTD.0000000000000462","article-title":"Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring","volume":"40","author":"Van Den Elsen","year":"2018","journal-title":"Ther Drug Monit"},{"key":"2021012006025969300_dkaa420-B25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2017.12.017","article-title":"Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment","volume":"68","author":"Zentner","year":"2018","journal-title":"Int J Infect Dis"},{"key":"2021012006025969300_dkaa420-B26","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piaa024","article-title":"Determination of rifampin concentrations by urine colorimetry and mobile phone readout for personalized dosing in tuberculosis treatment","author":"Szipszky","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021012006025969300_dkaa420-B27","doi-asserted-by":"crossref","first-page":"1702024","DOI":"10.1183\/13993003.02024-2017","article-title":"Lack of penetration of amikacin into saliva of tuberculosis patients","volume":"51","author":"van den Elsen","year":"2018","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B28","doi-asserted-by":"crossref","first-page":"1901903","DOI":"10.1183\/13993003.01903-2019","article-title":"Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin","volume":"55","author":"Van Den Elsen","year":"2020","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B29","doi-asserted-by":"crossref","first-page":"2000803","DOI":"10.1183\/13993003.00803-2020","article-title":"Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid","author":"van den Elsen","year":"2020","journal-title":"Eur Respir J"},{"key":"2021012006025969300_dkaa420-B30","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/cid\/ciz942","article-title":"Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis","volume":"70","author":"Alffenaar","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021012006025969300_dkaa420-B31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.17145\/jab.20.008","article-title":"Cross validation of liquid chromatography tandem mass spectrometry method for quantification of levofloxacin in saliva","volume":"6","author":"Ghimire","year":"2020","journal-title":"J Appl Bioanal"},{"key":"2021012006025969300_dkaa420-B32","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1128\/JCM.01248-17","article-title":"Membrane filtration is suitable for reliable elimination of Mycobacterium tuberculosis from saliva for therapeutic drug monitoring","volume":"55","author":"Van Den Elsen","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2021012006025969300_dkaa420-B33","first-page":"417","volume-title":"Molecular Spectroscopy. Atkins\u2019 Physical Chemistry","author":"Atkins","year":"2018"},{"key":"2021012006025969300_dkaa420-B34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1366\/000370255774634089","article-title":"The analysis of overlapping spectral absorption bands by derivative spectrophotometry","volume":"9","author":"Giese","year":"1955","journal-title":"Appl Spectrosc"},{"key":"2021012006025969300_dkaa420-B35","volume-title":"Uses of Derivative Spectroscopy, UV-Visible Spectroscopy","author":"Owen","year":"1995"},{"key":"2021012006025969300_dkaa420-B36","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/ac60214a047","article-title":"Smoothing and differentiation of data by simplified least squares procedures","volume":"36","author":"Savitzky","year":"1964","journal-title":"Anal Chem"},{"key":"2021012006025969300_dkaa420-B37","volume-title":"Applied Regression Analysis and Other Multivariable Methods","author":"Kleinbaum","year":"2013"},{"key":"2021012006025969300_dkaa420-B38","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkw164","article-title":"Pharmacokinetic\/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB","volume":"71","author":"Ghimire","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021012006025969300_dkaa420-B39","doi-asserted-by":"crossref","first-page":"e01092","DOI":"10.1128\/AAC.01092-18","article-title":"Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients","volume":"62","author":"Van den Elsen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012006025969300_dkaa420-B40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrmicro841","article-title":"Diagnostics for the developing world","volume":"2","author":"Mabey","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2021012006025969300_dkaa420-B41","doi-asserted-by":"crossref","first-page":"1901522","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/2\/423\/35925274\/dkaa420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/2\/423\/35925274\/dkaa420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T03:08:10Z","timestamp":1617332890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/2\/423\/5934856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,22]]},"published-print":{"date-parts":[[2021,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa420","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,10,22]]}}}